Trial Profile
Randomized, Double-Blinded, Placebo-Controlled, Open Label Positive- Controlled, Four-Way Crossover Study of the Electrocardiographic Effects of BMS-708163 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2011
Price :
$35
*
At a glance
- Drugs Avagacestat (Primary) ; Moxifloxacin
- Indications Alzheimer's disease; Bacterial infections
- Focus Pharmacodynamics
- Sponsors Bristol-Myers Squibb
- 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
- 15 Apr 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
- 15 Apr 2010 Actual number of patients added 62 as reported by ClinicalTrials.gov.